World Drug and Medication: Osteosarcoma – Pipeline Review, H1 2012

• Publication date: April 2013
• Report size: 74 pages

This report provides data on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. 'Osteosarcoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor pres...

This report provides data on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. 'Osteosarcoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Osteosarcoma.
- A review of the Osteosarcoma products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteosarcoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Osteosarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents
Data table of Contents 2
List of Tables 7
List of Figures 7
Introduction 9
Global March kets Direct Report Coverage 9
Osteosarcoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Osteosarcoma 11
Osteosarcoma Therapeutics under Development by Firms 13
Osteosarcoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Osteosarcoma Therapeutics – Products under Development by Firms 21
Osteosarcoma Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Osteosarcoma Therapeutics Development 24
Eli Lilly and Firms 24
Merck & Co., Inc. 25
ZIOPHARM Oncology, Inc. 26
Advaxis, Inc. 27
Oncolytics Biotech Inc. 28
Simcere Pharmaceutical Group 29
Hawthorn Pharmaceuticals, Inc. 30
Epeius Biotechnologies Corporation 31
Osteosarcoma – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Reolysin - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ADXS31-164 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SCH 717454 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BMTP-11 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Rexin-G - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Thiotepa + Stem Cell Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Liposomal Vincristine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Alimta - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Sodium Thiosulfate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cyclophosphamide + Sirolimus - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Genetically Modified T Cells - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Torisel - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cisplatin + Doxorubicin + Methotrexate + Pamidronate Disodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Filgrastim + Cisplatin + Doxorubicin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ET-743 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cisplatin + Doxorubicin + Etoposide + Ifosfamide + Methotrexate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PEG-interferon Alfa-2b + Cisplatin + Doxorubicin + Methotrexate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Recombinant Interferon Alpha + Etoposide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Zoledronic Acid + Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Zoledronic Acid - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Methotrexate + Adrimycin + Cisplatin + Ifosfamide - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Methotrexate + Adrimycin + Cisplatin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AYRPVSRNI + IFA - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AYRPVSRNI + IFA + Interferon Alpha - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
High Dose Methotrexate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Temsirolimus + Valproic Acid - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
G-CSF + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Radiation Therapy + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 78
G-CSF + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Radiation Therapy + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 80
Trimetrexate + Leucovorin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
GW786034 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Methotrexate + Cisplatin + Doxorubicine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
Cisplatin + Doxorubicin + Methotrexate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 86
Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Docetaxel + Gemcitabine + Filgrastim + Pegfilgrastim - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
GM-CSF - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Afinitor - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
haw mAb11 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RO4929097 + Dexamethasone - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Zymafos + Etoposide + Carboplatin - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Osteosarcoma Therapeutics – Drug Profile Updates 99
Osteosarcoma Therapeutics – Discontinued Products 103
Osteosarcoma Therapeutics - Dormant Products 104
Osteosarcoma – Product Development Milestones 106
Featured News & Press Releases 106
June 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex 106
October 12, 2009: Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine 107
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109

List of Tables

Number of Products Under Development for Osteosarcoma, H1 2012 11
Products under Development for Osteosarcoma – Comparative Analysis, H1 2012 12
Number of Products under Development by Firms, H1 2012 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Comparative Analysis by Late Stage Development, H1 2012 17
Comparative Analysis by Mid Clinical Stage Development, H1 2012 18
Comparative Analysis by Early Clinical Stage Development, H1 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 20
Products under Development by Firms, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 22
Eli Lilly and Firms, H1 2012 24
Merck & Co., Inc., H1 2012 25
ZIOPHARM Oncology, Inc., H1 2012 26
Advaxis, Inc., H1 2012 27
Oncolytics Biotech Inc., H1 2012 28
Simcere Pharmaceutical Group, H1 2012 29
Hawthorn Pharmaceuticals, Inc., H1 2012 30
Epeius Biotechnologies Corporation, H1 2012 31
Assessment by Monotherapy Products, H1 2012 32
Assessment by Combination Products, H1 2012 33
Assessment by Stage and Route of Administration, H1 2012 35
Assessment by Stage and Molecule Type, H1 2012 37
Osteosarcoma Therapeutics – Drug Profile Updates 99
Osteosarcoma Therapeutics – Discontinued Products 103
Osteosarcoma Therapeutics – Dormant Products 104

List of Figures

Number of Products under Development for Osteosarcoma, H1 2012 11
Products under Development for Osteosarcoma – Comparative Analysis, H1 2012 12
Products under Development by Firms, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 17
Mid Clinical Stage Products, H1 2012 18
Early Clinical Stage Products, H1 2012 19
Pre-Clinical Stage Products, H1 2012 20
Assessment by Monotherapy Products, H1 2012 32
Assessment by Combination Products, H1 2012 33
Assessment by Route of Administration, H1 2012 34
Assessment by Stage and Route of Administration, H1 2012 35
Assessment by Molecule Type, H1 2012 36
Assessment by Stage and Molecule Type, H1 2012 37